Natera, Inc.(NTRA) - Stock detail

Natera, Inc.

US
NTRA
Natera, Inc.(Listing date: 07/02/2015)

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technologies that it is applying to transform disease management worldwide. The company's cell-free DNA (cfDNA) technology combines novel molecular analytical methods that can reliably measure many informative regions across the entire genome from samples as small as a single cell, as well as statistical algorithms that incorporate data provided by the broader scientific community to identify genetic variations covering a wide range of serious diseases with high precision and high coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care for protecting health and inform earlier and more targeted interventions to help achieve longer, healthier lives.

AI Risk OfficerSell
Generated at:2026-03-14 05:52:03
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-03-13
  • Technical Breakdown Dominates: The conservative analyst correctly identifies the breach of critical support at $188.49 with bearish MACD momentum as institutional distribution, while the aggressive analyst misjudges this as temporary oversold conditions suitable for accumulation.
  • Valuation Unsustainable: Despite the aggressive analyst highlighting 40% YoY revenue growth, the conservative analyst's focus on negative earnings ($208M net loss) and lofty P/S 11.55x is more compelling in current macro conditions, making neutral's gradual approach risky.
  • Macro Risks Are Real: The 8.3% single-day drop on PPI data confirms NTRA's vulnerability to interest rate volatility, supporting conservative's caution over aggressive's fundamental optimism and neutral's balanced stance.
  • Target Alignment Valid: The original $165 target based on derated P/S ~10x remains appropriate given technical breakdown and macro headwinds, countering aggressive's asymmetric risk-reward claim of 12.2% downside being improbable.
Aggressive views
  • Oversold conditions present buying opportunity
  • Strong fundamentals: 40% YoY revenue growth, 64.75% gross margin
  • Growth catalysts: Zenith Genomics launch, Signatera clinical data
  • Asymmetric risk-reward profile favors upside potential
  • Technical weakness is temporary chance to accumulate
Neutral views
  • Acknowledge weak technicals but strong fundamentals
  • Recommend trimming existing positions or small new positions
  • Suggest scaling in gradually to balance opportunity and risk
  • Avoid outright buying or selling in current conditions
  • Moderate approach given mixed signals
Conservative views
  • Strongly recommend selling due to unsustainable valuation
  • P/S 11.55x and P/B 25.42x are too high
  • Persistent negative earnings: trailing PE -103.56, forward PE -168.14
  • High macro sensitivity: 8.3% drop on PPI data
  • Technical breakdown: below all major moving averages
  • Wait for stabilization near $165 before considering entry

Decision

Decision summary

The conservative analyst presents the most compelling case, supported by the trader’s original analysis and current market context. Key points:

  • Technical Breakdown Dominates: The stock has breached critical support ($188.49 lower Bollinger Band) with accelerating bearish momentum (MACD histogram at -5.8577). This suggests institutional distribution, not retail profit-taking, indicating deeper downside risk. The aggressive analyst’s optimism on oversold conditions ignores the momentum-driven nature of this decline.
  • Valuation Unsustainable: Despite strong revenue growth, negative earnings ($208 million net loss in 2025) and lofty multiples (P/S 11.55x) are untenable in a macro environment sensitive to profitless growth stocks. The neutral analyst’s “trim or small position” approach underestimates how quickly valuation derating can occur amid rising rate concerns.
  • Macro Risks Are Real: The 8.3% single-day drop on February 27 due to PPI data confirms NTRA’s vulnerability. With interest rate expectations remaining volatile, high-growth, unprofitable stocks like NTRA are likely to face continued pressure. The aggressive analyst’s focus on fundamentals overlooks this systemic risk.
  • Target Alignment: The original trader plan targeted $165 based on estimated average cost basis and a derated P/S multiple (~10x). This remains valid given the lack of technical stabilization and fundamental catalysts to offset macro headwinds in the near term.

Trader plan

Execution plan

Execute Sell at current levels (~$188), with a stop-loss at $185 to protect against a brief squeeze.

Re-entry Consideration: Only reconsider buying if NTRA stabilizes above $214 with improving MACD and volume patterns, and/or valuation approaches $165 P/S ~10x forward estimates. Capital Allocation: Preserve capital for opportunities in less macro-sensitive, profitable growth stocks.

AI Risk Assessment Discussion
Round-by-round arguments
Round 1

Round 1 · Aggressive

  • An analyst recommends selling a stock at $187, targeting $165, citing a technical breakdown, negative momentum, and macro headwinds. The strategy aims to preserve capital for a potential 12% discounted re-entry, arguing this tactical move i

Detail Preview

Look, I completely understand why conservative and neutral analysts are hesitant here—they see negative earnings, high volatility, and a technical breakdown. But that's exactly why this SELL recommendation at $165 is such an aggressive, high-reward move. You're all missing the bigger picture: this isn't just risk management; it's about capitalizing on momentum to maximize short-term gains and reposition for explosive…

Round 1 · Neutral

  • Speaker critiques both aggressive and conservative analyst views on a stock. Acknowledges weak technicals but strong fundamentals, suggesting a moderate strategy of trimming or starting small positions instead of a binary buy/sell decision.

Detail Preview

Let me jump right into this debate between our aggressive and conservative analysts. I think both are missing crucial nuances in their arguments. Looking at the aggressive sell recommendation, I have to challenge the narrow focus here. Yes, the technicals look terrible - breakdown below all moving averages, negative MACD, oversold conditions. But recommending a sell at $187 targeting $165 ignores some fundamental str…

Round 1 · Conservative

  • Speaker expresses strong concerns about a stock, recommending SELL due to significant financial losses, negative technical indicators, and high sensitivity to macro risks, advising capital preservation.

Detail Preview

I understand my colleagues are seeing potential opportunities here, but I have serious concerns about their optimistic interpretations. Let me address why this SELL recommendation actually makes sense from a risk management perspective. First, to the fundamental analyst who sees this as a HOLD opportunity - you're focusing too much on revenue growth while ignoring the alarming financial reality. This company lost $20…

Round 2

Round 2 · Aggressive

  • A speaker argues against selling or trimming a stock, viewing its oversold technicals as a buying opportunity. They believe strong fundamentals, growth catalysts, and an asymmetric risk-reward profile justify a high-conviction position, dis

Detail Preview

Look, I respect both perspectives here, but you're both missing the forest for the trees. The conservative approach is downright cowardly - selling at these levels means locking in losses right before massive catalysts hit. And the neutral "trimming" strategy? That's just hedging your bets when conviction is what delivers alpha. Let me break this down: The technical breakdown everyone's panicking about has created a…

Round 2 · Neutral

  • Speaker critiques two extreme stock analyses: one overly aggressive, ignoring bearish technicals
  • the other overly conservative, ignoring strong fundamentals. Advocates for a moderate strategy of scaling in slowly, acknowledging both strong

Detail Preview

Let me jump in here because I think both of you are missing the bigger picture by focusing too much on your extreme positions. To the aggressive analyst: You're getting too excited about this oversold bounce play. Yes, the technicals are oversold and there are solid fundamentals, but you're ignoring how brutal this technical breakdown actually is. The stock isn't just dipping - it's broken below all major moving aver…

Round 2 · Conservative

  • 该发言主张采取保守投资策略，认为该公司的巨额亏损、负面技术指标、高估值及宏观经济风险被低估
  • 建议完全规避风险，等待技术面稳定和估值降至165美元后再考虑入场，以保护资本

Detail Preview

I understand the aggressive analyst sees this as a buying opportunity and the neutral analyst wants a moderate approach, but both are underestimating the severe risks here. Let me explain why a conservative stance is absolutely necessary. First, to the aggressive view: calling this an "asymmetric risk-reward" opportunity ignores the fundamental reality that this company is burning through cash with no clear path to p…

Assessment complete